Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation Outcomes in Patients with Hematologic Malignancies after Allogeneic Peripheral Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 7, 2006, Pages 719-728

  Kim, Dong Hwan ^a,b   Won, Dong Il ^a   Lee, Nan Young ^a   Sohn, Sang Kyun ^a   Suh, Jang Soo ^a   Lee, Kyu Bo ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Allogeneic peripheral blood stem cell transplantation; CD34+ cells; CD56+ natural killer cell; CD8+ cytotoxic T cell; Engraftment kinetics

Indexed keywords

ACICLOVIR; BUSULFAN; CD34 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CIPOL N; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; METRONIDAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE REGIMEN; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NEUTROPHIL; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33745145002     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.03.005     Document Type: Article

References (22)

1. Brown R.A., Adkins D., Goodnough L.T., et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 15 (1997) 3067
2. Mohty M., Bilger K., Jourdan E., et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 17 (2003) 869
3. Jiang Z., Adams G.B., Hanash A.M., Scadden D.T., and Levy R.B. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 8 (2002) 588
4. Urbano-Ispizua A., Rozman C., Pimentel P., et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 97 (2001) 383
5. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343
6. Cao T.M., Shizuru J.A., Wong R.M., et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 105 (2005) 2300
7. Kim DH, Won DI, Lee NY, et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Hematol. 2005. In press.
8. Sohn S.K., Kim D.H., Kim J.G., et al. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Bone Marrow Transplant 34 (2004) 63
9. Kim D.H., Kim J.G., Sohn S.K., et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 125 (2004) 217
10. Sohn S.K., Kim J.G., Chae Y.S., et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors. predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 18 (2003) 10
11. Sohn S.K., Kim J.G., Sung W.J., et al. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. J Clin Apheresis 18 (2003) 186
12. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825
13. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204
14. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98 (2001) 3221
15. Sohn S.K., Kim J.G., Kim D.H., Lee N.Y., Suh J.S., and Lee K.B. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 31 (2003) 967
16. Lee S.H., Lee M.H., Lee J.H., et al. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant 11 (2005) 122
17. Storek J., Dawson M.A., Storer B., et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97 (2001) 3380
18. Baron F., Little M.T., and Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 19 (2005) 153
19. Powles R., Singhal S., Treleaven J., Kulkarni S., Horton C., and Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 91 (1998) 3481
20. Kumar S., Chen M.G., Gastineau D.A., et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 28 (2001) 951
21. Kumar S., Chen M.G., Gastineau D.A., et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 17 (2003) 1865
22. Jiang Y.Z., Barrett A.J., Goldman J.M., and Mavroudis D.A. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 74 (1997) 1